144 results on '"Nguyen, Quan"'
Search Results
2. Reply
3. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
4. Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples
5. A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration
6. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the m Acula in Diabetes (READ-2) Study
7. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 1
8. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 2
9. Reply
10. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
11. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU)
12. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis
13. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III
14. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
15. Reply
16. Twenty-four–Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study
17. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)
18. Intravitreal Aflibercept for Diabetic Macular Edema
19. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies
20. Reply
21. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment
22. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study
23. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
24. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion
25. Intravitreal Aflibercept for Diabetic Macular Edema
26. Author reply
27. Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
28. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
29. Association of Retinal Sensitivity to Integrity of Photoreceptor Inner/Outer Segment Junction in Patients with Diabetic Macular Edema
30. Putting Theories and Results into Practice
31. Introduction: Neovascular Age-Related Macular Degeneration
32. Aqueous Levels of Fluocinolone Acetonide after Administration of Fluocinolone Acetonide Inserts or Fluocinolone Acetonide Implants
33. Author reply
34. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
35. Evaluation of the siRNA PF-04523655 versus Ranibizumab for the Treatment of Neovascular Age-related Macular Degeneration (MONET Study)
36. One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
37. Ranibizumab for Diabetic Macular Edema
38. Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration
39. The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing
40. A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States
41. Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes
42. Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
43. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
44. Punctate Inner Choroidopathy
45. Mycophenolate Mofetil Therapy for Inflammatory Eye Disease
46. Heparin-induced antiheparin-platelet antibody associated with retinal venous thrombosis1 1The scientific work presented in this manuscript was completed while Drs. Nguyen and Do were a Retina Fellow and a Medical Intern, respectively, at Harvard Medical School. Drs. Nguyen and Do are currently at the Wilmer Ophthalmological Institute.
47. Heparin-induced antiheparin-platelet antibody associated with retinal venous thrombosis1 <FN ID="FN1"><NO>1</NO>The scientific work presented in this manuscript was completed while Drs. Nguyen and Do were a Retina Fellow and a Medical Intern, respectively, at Harvard Medical School. Drs. Nguyen and Do are currently at the Wilmer Ophthalmological Institute.</FN>
48. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
49. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy Long-Term Outcomes of the Phase III RIDE and RISE Trials
50. A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.